Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).

The technology is a further treatment option after standard oral treatments have been unsuccesful. The overall cost of treatment is not deemed to be significant because there is a reduction in the number of patients requiring bladder instillations.

Pentosan polysulfate sodium has a discount that is commercial in confidence. For enquiries about the patient access scheme please contact Email: infouk@consilienthealth.com Telephone: 020 3751 1888.

This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.


This page was last updated: